Analytical Data
-
Gene name
LGALS9
- Application
-
Alternative Names
LGALS9；Galectin-9
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O00182
-
Expression Region
207-355aa
-
AA Sequence
MFSTPAIPPMMYPHPAYPMPFITTILGGLYPSKSILLSGTVLPSAQRFHINLCSGNHIAFHLNPRFDENAVVRNTQIDNSWGSEERSLPRKMPFVRGQSFSVWILCEAHCLKVAVDGQHLFEYYHRLRNLPTINRLEVGGDIQLTHVQT
-
Molecular Weight
23.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Galectin-9 (LGALS9) is a member of the galectin family, which are β-galactoside-binding proteins involved in various cellular processes, including cell adhesion, migration, and immune response modulation. Originally identified as a protein associated with immune cell regulation, LGALS9 has drawn significant attention due to its dual roles in promoting immune tolerance and modulating inflammation. It interacts with various receptors on immune cells, influencing cell differentiation and apoptosis, making it a key player in conditions like cancer, autoimmune diseases, and infections. Its expression has been linked to the progression of tumors and the establishment of a tumor-friendly microenvironment, thus highlighting its potential as a therapeutic target. Furthermore, LGALS9 has emerged as a promising biomarker for certain diseases, providing insights into disease progression and treatment efficacy. The development and study of recombinant LGALS9 protein enhance our understanding of its biochemical properties and functional mechanisms, paving the way for novel therapeutic approaches that harness its immunomodulatory capabilities. As researchers delve deeper into the structure-function relationships and the signaling pathways influenced by LGALS9, the potential for diagnostic and therapeutic applications continues to expand, marking LGALS9 as a significant focus in immunology and cancer research.
